Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 15:12:636375.
doi: 10.3389/fimmu.2021.636375. eCollection 2021.

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?

Anne Marit Sponaas  1 , Anders Waage  1   2 , Esten N Vandsemb  1 , Kristine Misund  1 , Magne Børset  1   3 , Anders Sundan  1 , Tobias Schmidt Slørdahl  1   2 , Therese Standal  1   4
Affiliations
Review

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?

Anne Marit Sponaas et al. Front Immunol. .

Abstract

In this review article we discuss the role of the memory T cells in multiple myeloma (MM) and how they may influence immune responses in patients that received immunomodulating drugs and check point therapy.

Keywords: T cells; checkpoint therapy; immunomodulating drugs; multiple myeloma; virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Illustrating re-activation of effector T-cells to viral antigens after combined IMiD and checkpoint therapy. (Created with BioRender.com).
See this image and copyright information in PMC

References

    1. Mateos MV, Orlowski RZ, Ocio EM, Rodriguez-Otero P, Reece D, Moreau P, et al. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. (2019) 186:e117–21. 10.1111/bjh.15946 - DOI - PubMed
    1. Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. (2019) 6:e459–69. 10.1016/S2352-3026(19)30110-3 - DOI - PubMed
    1. Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. (2019) 6:e448–58. 10.1016/S2352-3026(19)30109-7 - DOI - PubMed
    1. Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. (2016) 73:1569–89. 10.1007/s00018-016-2135-z - DOI - PMC - PubMed
    1. Nakamura K, Kassem S, Cleynen A, Chretien ML, Guillerey C, Putz EM, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. (2018) 33:634–48.e635. 10.1016/j.ccell.2018.02.007 - DOI - PubMed

Publication types

MeSH terms